BUCK INSTITUTE FOR RESEARCH ON AGING

Metformin's Potential in Slowing Aging to be Examined in TAME Trial

a year ago

• The TAME Trial will investigate metformin's potential to prevent age-related diseases like heart disease, cancer, and cognitive decline in healthy older adults. • Metformin, a widely used diabetes drug, has shown anti-inflammatory effects and reduced risk of cancer, dementia, and cardiovascular issues in observational studies. • The trial aims to understand metformin's mechanisms, such as improving cellular energy through autophagy and reducing inflammation and oxidative stress. • Funding for the TAME Trial, estimated at $45-70 million, is primarily sourced from philanthropists and the National Institute on Aging due to metformin's generic status.